Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Hoffmann-La Roche
Eli Lilly and Company
Jazz Pharmaceuticals
ITM Solucin GmbH
BeiGene
Taproot Health
Catalysis SL
Y-mAbs Therapeutics
Eisai Inc.
Lisata Therapeutics, Inc.
DNAtrix, Inc.
Novartis
Novartis
Pfizer
Pfizer
Daiichi Sankyo